-transparent.png){kind=logo}
The authors review the literature regarding the pharmacokinetics of long-acting injectable neuroleptic drugs (LINS). There are important differences between LINS and oral neuroleptics that affect their pharmacokinetics. By avoiding first pass metabolism in gut and liver, LINS result in lower circulating concentrations of metabolites than are found after oral administration. In addition, LINS take more time to reach a stable steady state than their oral counterparts. The clinical significance of these pharmacokinetic properties is discussed. The authors recommend that when patients are being changed from oral neuroleptics to LINS, that this conversion be done gradually over several months.
S R Marder, and
J W Hubbard, and
T Van Putten, and
K K Midha
November 1972,
Acta psychiatrica Belgica,
S R Marder, and
J W Hubbard, and
T Van Putten, and
K K Midha
July 1977,
Drug and therapeutics bulletin,
S R Marder, and
J W Hubbard, and
T Van Putten, and
K K Midha
June 2022,
Psychiatrike = Psychiatriki,
S R Marder, and
J W Hubbard, and
T Van Putten, and
K K Midha
January 1970,
Psychiatria, neurologia, neurochirurgia,
S R Marder, and
J W Hubbard, and
T Van Putten, and
K K Midha
October 1982,
Psychopharmacology bulletin,
S R Marder, and
J W Hubbard, and
T Van Putten, and
K K Midha
September 2018,
Journal of patient safety,
S R Marder, and
J W Hubbard, and
T Van Putten, and
K K Midha
January 1975,
International journal of neurology,
S R Marder, and
J W Hubbard, and
T Van Putten, and
K K Midha
September 2021,
Journal of psychiatry & neuroscience : JPN,
S R Marder, and
J W Hubbard, and
T Van Putten, and
K K Midha
July 1978,
Pharmakopsychiatrie, Neuro-Psychopharmakologie,
S R Marder, and
J W Hubbard, and
T Van Putten, and
K K Midha
March 2006,
Alcoholism, clinical and experimental research,
